Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

NCT00383149 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT00383149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00383149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Lead sponsor
R-Pharm
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
June 30, 2009
Enrollment
58 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer